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The amount and distribution of dystrophin protein in
myofibers and muscle is highly variable in Becker
muscular dystrophy and in exon-skipping trials for
Duchenne muscular dystrophy. Here, we investigate
a molecular basis for this variability. In muscle
from Becker patients sharing the same exon 45–47
in-frame deletion, dystrophin levels negatively
correlate with microRNAs predicted to target dystro-
phin. Seven microRNAs inhibit dystrophin expres-
sion in vitro, and three are validated in vivo (miR-
146b/miR-374a/miR-31). microRNAs are expressed
in dystrophic myofibers and increase with age and
disease severity. In exon-skipping-treated mdx
mice, microRNAs are significantly higher in muscles
with low dystrophin rescue. TNF-a increases micro-
RNA levels in vitro whereas NFkB inhibition blocks
this in vitro and in vivo. Collectively, these data
show that microRNAs contribute to variable dystro-
phin levels in muscular dystrophy. Our findings
suggest a model where chronic inflammation in
distinct microenvironments induces pathological
microRNAs, initiating a self-sustaining feedback
loop that exacerbates disease progression.INTRODUCTION
Duchenne muscular dystrophy (DMD) is caused by mutations in
the dystrophin (DMD) gene that disrupt the open reading frame
and prevent its protein translation (Chamberlain et al., 1987;
Hoffman et al., 1987a, 1987b, 1988). Becker muscular dystrophy
(BMD) is less severe and results from DMD mutations that pre-
serve the reading frame. BMD-causing mutations lead to trans-
lation of a truncated dystrophin, which is expressed at lower
and more variable levels than full-length dystrophin (Beggs
et al., 1991; Hoffman et al., 1989; Kesari et al., 2008).1678 Cell Reports 12, 1678–1690, September 8, 2015 ª2015 The AuDystrophin content in BMD muscle varies within myofibers,
between adjacent fibers, and between different patients, even
when the same deletion mutation is shared. Dystrophin levels
partly correlate with disease severity. Compared to normal mus-
cle, dystrophin levels of 3%–15% are seen in severe BMD,
whereas >20% are associated with milder disease (Hoffman
et al., 1988, 1989). BMD genotype-phenotype associations
have previously been investigated to determine whether there
is a mutation-specific basis for inter-patient variation in dystro-
phin levels (Beggs et al., 1991; Cirak et al., 2011; Kesari et al.,
2008; Koenig et al., 1987; Mendell et al., 2013; van den Bergen
et al., 2014). These studies show that, whereas greater disease
severity is seen with amino- and carboxyl-terminal deletions,
there is high variation in both dystrophin expression and clinical
symptoms in patients with mutations in the central rod domain,
even when the same exons are deleted.
The most common in-frame BMD deletion is of exons 45–47
(BMD D45–47), which codes for 150 amino acids in the central
rod domain. We and others have reported variable dystrophin
in BMD D45–47 muscle (5%–80%; Kesari et al., 2008; van den
Bergen et al., 2014). These studies found little correlation be-
tween dystrophin amount and clinical phenotype; however,
BMD patients with <10% dystrophin exhibited a more severe
clinical picture (Kesari et al., 2008; van den Bergen et al.,
2014). BMD D45–47 patients should, in theory, show similar
gene expression, comparable mRNA stability, and produce an
identical truncated protein with equivalent levels/stability. In
contrast, the observed dystrophin content in these muscles var-
ied significantly, suggesting amechanism of post-transcriptional
dystrophin regulation.
A promising approach to induce de novo dystrophin in DMD
muscle is exon skipping, where antisense oligonucleotides drive
alternative splicing to produce a BMD-like dystrophin protein
product. Although extensive pre-clinical studies have provided
proof of principle of this approach, dystrophin levels varied
within and between muscle groups (Yokota et al., 2009, 2012).
Two clinical trials have also observed uneven dystrophin rescue
(Cirak et al., 2011; Mendell et al., 2013).
We hypothesized thatmolecularmechanisms causing variable
dystrophin protein levels in BMD are shared with those causingthors
variability in exon skipping. To prevent introduction of confound-
ing variables (differences in dystrophin transcript and protein
stability), we utilized BMD muscles from patients with the same
dystrophin D45–47 exon deletion as the initial discovery data
set. Our preliminary data showed that dystrophin mRNA levels
are maintained in BMD D45–47 muscle whereas dystrophin pro-
tein levels are variable. Given this, we investigated the role of
microRNAs (miRNAs) in regulating post-transcriptional dystro-
phin levels.
RESULTS
Variable Dystrophin in D45–47 BMD Patient Muscles
Does Not Correlate with Transcript Levels
We carried out studies on ten BMD patient biopsies harboring an
exon 45–47 deletion mutation (BMD D45–47; Table S1). Dystro-
phin western blot was performed with patient muscle and a stan-
dard curve of healthy muscle (‘‘normal’’) showing a dynamic
linear range (Figures 1A and S1A). Normalized dystrophin was
variable, ranging from 8% to 63% (Figure 1B).
For subsequent studies, sampleswere stratified basedondys-
trophin levels. Groups were defined as ‘‘high,’’ corresponding to
>20%dystrophin, and ‘‘low,’’ corresponding to <20%dystrophin
(Figure S1B) based on reports showing dystrophin levels greater
than 20% are needed to fully protect muscle fibers (van Putten
et al., 2012). Dystrophin mRNA measured by qRT-PCR showed
no correlation with dystrophin protein (Figures 1B and S1C).
Neither RT-PCR using primers flanking exons 44 and 48 nor
qRT-PCRusing customprobes against alternatively spliced tran-
scripts showed evidence of alternative splicing (data not shown).
Predicted miRNA Binding Sites in the Dystrophin 30 UTR
Correspond to miRNAs Elevated in Dystrophic Muscle
Given the lack of correlation between dystrophin mRNA and pro-
tein levels, we hypothesized miRNAs may post-transcriptionally
regulate dystrophin. Seventy-eight potential miRNA-binding
sites for 67 distinct miRNAs were identified in evolutionarily
conserved regions of the 2.7-kb dystrophin 30 UTR (Figure S1D).
miRNA profiling was performed with BMD D45–47 (n = 10),
normal (n = 6), and DMD muscle biopsies (n = 5) with TaqMan
TLDA Arrays containing probes for 51/67 miRNAs predicted to
bind the dystrophin 30 UTR. In BMD low samples, 14 miRNAs
showed significant upregulation (1.5-fold to 17-fold; Figure 1C).
In contrast, only five miRNAs were elevated in BMD high sam-
ples (Figure 1C). In an additional analysis, the number of elevated
miRNAs (%1.5-fold) in each BMD sample showed a modest in-
verse correlation when plotted as a continuous variable against
dystrophin protein (Figure 1D). Similarly, individual miRNA levels
(miR-146b, miR-374a, and miR-382 shown as examples; Fig-
ure 1E) showed inverse correlations with dystrophin. Together,
these data show dystrophin-targeting miRNAs (herein referred
to as DTMs) are inversely related to dystrophin levels in BMD
D45–47 muscle.
In an additional analysis, we found five DTMs elevated (3.6-
to 25.1-fold) in both DMD and BMD low muscle (miR-146-5p,
miR-382, miR-758, miR-214, and miR-494; Figure S1E). Dystro-
phin-targeting miR-31 was also upregulated in DMD muscle
(Figure S1E).Cell ReDTMs Inhibit Dystrophin Protein Translation In Vitro
To determine whether DTMsmodulate dystrophin protein levels,
we constructed a reporter containing the 2.7-kb dystrophin
30 UTR downstream of Renilla reniformis luciferase; this reporter
co-expressed Firefly luciferase from a separate promoter, thus
providing a robust internal transfection control (Figure 2A). This
reporter was co-transfected into C2C12 myoblasts along with
one of 14 miRNAs upregulated in BMD low muscle (Table S2).
Seven miRNAs inhibited dystrophin expression (miR-31, miR-
146a, miR-146b-5p, miR-223, miR-320a, miR-374a, and miR-
382), two enhanced expression (miR-195/miR-758), and five
had no effect (Figure 2B).
We tested the most potent DTMs in human myotubes in vitro.
Immortalized human myoblasts were transfected with the indi-
catedmiRNAs or control and differentiated intomyotubes.West-
ern blot showed all miRNAs reduced dystrophin to <20% of
normal levels (Figure 2C).
Using miRNAs showing the strongest inhibition (miR-146b,
miR-31, and miR-374a), we determined whether miRNAs could
have an additive or synergistic effect in combination. Here, we
created a miRNA mix (‘‘Biomix’’) composed of miRNA levels
that approximated expression in dystrophic muscle biopsies
based on Cq levels from miRNA arrays (70% miR-146b, 25%
miR-374a, and 5% miR-31; Figure 2D; Table S2). At 1 nM, the
Biomix inhibited reporter activity more than any single miRNA
at the same concentration (Figure 2D), indicating DTMs may
work in concert to inhibit dystrophin.
To determine the specificity of miRNA-mediated dystrophin
inhibition, we mutated specific miRNA response elements
(MREs) in the 30 UTR reporter (Figure 2E). Mutants were made
for each miRNA in the Biomix, including disruption of one miR-
374a MRE. We anticipated, however, this mutant would have
little or no effect due to the other two MREs located within the
dystrophin 30 UTR. Results showed miR-146a/b MRE mutagen-
esis attenuated inhibition both of miR-146b and miR-146a and
miR-31 MRE mutagenesis alleviated miR-31-specific inhibition
(Figure 2F). miR-374aMREmutagenesis, however, had no effect
on miR-374a-mediated inhibition (Figure 2F), likely due to the
two functional miR-374a MREs remaining.
DTMs Regulate Dystrophin In Vivo
Next, we tested the effects of DTMs in wild-typemice in vivo. The
Biomix (miRNA) was injected into the right tibialis anterior (TA) of
6-week-old C57BL10/J mice; the left TA received scrambled
control (CTRL) (Table S2). Seven days post-injection, muscles
were harvested and analyzed for miRNA and dystrophin. qRT-
PCR showed successful intramuscular delivery of exogenous
miRNAs (Figure S2A). At the injection site (indicated by tattoo
dye), immunofluorescence showed reduced dystrophin in
miRNA, but not in CTRL-injected mice (Figure 3A). qRT-PCR
showed dystrophin mRNA was not affected (Figure S2B),
consistent with translation inhibition as the primary mechanism
of action.
In the previous experiment, miRNA delivery was restricted to a
small region surrounding the injection site. Thus, we performed a
second experiment where muscles were injured via notexin prior
tomiRNA injection. This approach also had the effect of removing
endogenous dystrophin in mature myofibers, enabling us toports 12, 1678–1690, September 8, 2015 ª2015 The Authors 1679
Figure 1. BMD D45–47 Muscle Shows Variable Dystrophin Protein Levels
(A) Western blot of BMD D45–47 muscle demonstrates variable dystrophin. Desmin and Coomassie stain for myosin heavy chain (MYHC) were used as loading
controls.
(B) Dystrophin transcript levels (qRT-PCR) do not correlate with dystrophin protein (Spearman’s correlation; rs = 0.0332; p = 0.412).
(C–E) DTMs increase in BMD low dystrophin muscle. TaqMan TLDA miRNA arrays performed with normal (n = 6) and BMD D45–47 (n = 10) muscle. (C) Elevated
DTMs in BMD muscle with low dystrophin are shown. Table lists DTMs elevated in BMD high and low muscle; fold changes and p values are shown (high >20%
dystrophin [n = 6] and low <20% dystrophin [n = 4] versus normal [ANOVA with post hoc contrast groups: normal versus low; normal versus high]). (D) Inverse
correlation between dystrophin and DTMs is shown (defined in each sample usingR1.5-fold increase versus normal). Plot shows miRNAs detected in individual
muscle versus percent dystrophin (Spearman’s correlation; rs =0.726; ***p < 0.0006). (E) DTMs inversely correlate with dystrophin protein. Plot shows miRNAs
versus percent dystrophin protein in BMD and normal muscle (Spearman’s correlation; rs = 0.691;**p = 0.0013; rs = 0.610, **p = 0.0048; rs = 0.732,
**p = 0.0011 for miR-146b-5p, miR-374a, and miR-382, respectively).
Refer also to Figure S1 and Table S1.determine whether injected miRNAs inhibit de novo dystrophin
during myogenic regeneration (half-life of dystrophin in mature
myofibers is 2 months; Wu et al., 2012). The TA muscles of1680 Cell Reports 12, 1678–1690, September 8, 2015 ª2015 The Au6-week-old C57BL/10ScSnJ wild-type mice were injected with
100 mg notexin. Four days after the initial injury, mice were in-
jected with the miRNA Biomix or CTRL. Mice were harvestedthors
7 days post-injury, when dystrophin expression becomes visible
inmyotubes (Hoshino et al., 2002).Western blot showed reduced
dystrophin in miRNA, but not in CTRL-injected mice (Figure 3B).
Immunofluorescence corroborated these results (Figure 3C).
DTMs in Dystrophic Muscle Increase with Age
Golden retriever muscle dystrophy dogs (GRMD) exhibit variable
histopathology, similar to DMD boys (Cooper et al., 1988; Shi-
matsu et al., 2005; Smith et al., 2011; Valentine et al., 1988).
Given this, we assessed DTMs in GRMD muscle. We first
measured DTMs in 6-month-old GRMD vastus lateralis (VL) as
it is histologically severe and similar to the VL of DMD patients.
miR-146b, miR-146a, and miR-223 were elevated in the GRMD
VL (n = 9; 50-fold, 3-fold, and 8-fold, respectively) as compared
to wild-type (Figure 4A; Table S3 for TaqMan assay information).
DTMswere alsomeasured in GRMDcranial sartorius (CS), which
is mildly affected in both dogs and humans (Calabia-Linares
et al., 2011; Lemaire et al., 1988; Nghiem et al., 2013). miR-
146b, miR-146a, miR-223, and miR-382 were elevated (n = 9;
25-fold, 1.3-fold, 2.5-fold, and 4-fold) in GRMD CS, albeit at
slightly lower levels as compared to the GRMD VL (Figure S3A).
Supporting this, DTMswere similarly elevated inmdx gastrocne-
mius (Figure S3B).
Next, we determined whether DTMs correspond with dystro-
phic disease severity, utilizing VLs from 1- or 6-month-old
GRMD and wild-type dogs. Three miRNAs (miR-146b/miR-
146a/miR-223) increased with age (n = 6; Figure 4B). Separately,
we performed a smaller longitudinal analysis using VL muscle
taken serially from GRMD (n = 4) or wild-type (n = 4) dogs over
a period of 6 months. miR-146b, miR-146a, and miR-223
increased in 100% of GRMD dogs from 1 to 6 months whereas,
in wild-type, these miRNAs either decreased or showed a
smaller change (Figure S3C). To further demonstrate that
DTMs are associated with disease progression, we analyzed
TAs of 12-day- and 8-week-oldmdxmice. We observed marked
increases in miR-223 and miR-31 correlating with age (Fig-
ure 4C). miR-146a/miR-146b were equally elevated in both
ages ofmdxmice, but this is likely due to early pre-symptomatic
activation of NFkB as previously observed in newborn DMD
patients (Chen et al., 2005). Consistent with previous studies
(Hamrick et al., 2010), when DTMs were assessed in wild-type
mice, only miR-382 levels were significantly altered (decreased
to 10% in older mice); however, the change was opposite to
the direction of the mdx genotype effect (Figure S3D).
To see whether DTMs were expressed in muscle cells, mature
myofibers were enzymatically dissociated from the extensor dig-
itorum longus muscle (EDL) of 8-week-old mdx and wild-type
mice. miR-146b, miR-146a, miR-31, and miR-223 were elevated
inmdxwhole EDL (Figure 4D) and in purified fibers (Figure 4E). In
mdx myotubes in vitro, four DTMs increased during differentia-
tion (Figure S3E), suggesting a role in regeneration. Together,
these data show miRNAs become increasingly elevated in older
dystrophic muscle and DTMs are not associated with the normal
aging process in muscle.
DTMs Reduce Exon Skipping Success
We tested whether DTMs contribute to variable dystrophin
rescue observed in exon skipping. Four-week-old mdx miceCell Rewere given a single 800 mg/kg intravenous injection of exon-
23-targeting morpholino and were sacrificed after 1 month.
From one mouse, adjacent sections of TA, gastrocnemius, and
diaphragm muscles were analyzed for dystrophin protein by
mass spectrometry (Brown et al., 2012) and for DTMs by qRT-
PCR. We detected high dystrophin levels in the TA (40%)
whereas diaphragm and gastrocnemius showed lower levels
(5%; Figure 5A). Conversely, DTMs were low in the TA (miR-
146a/miR-374a/miR-223/miR-320a/miR-382) and high in the
gastrocnemius and diaphragm muscles (Figure 5A).
To determine whether DTMs contributed to intra-animal exon
skipping variability, two additional morpholino-injected mice
were studied. DTMs in mdx triceps, gastrocnemius, and TA
were measured (n = 9 muscles tested; seven miRNA mea-
sures/muscle). Muscles were stratified into miRNA low, moder-
ate, or high groups and plotted against % dystrophin. We found
the miRNA low group showed quite high dystrophin whereas the
high group had lower dystrophin levels (Figure 5B). These data
suggest DTMs may contribute to inter- and intra-subject vari-
ability of dystrophin rescue in exon skipping studies.
DTMs Are Induced by Pro-inflammatory TNF-a in
Myogenic Cells
TwoDTMs are induced by NFkB;miR-146a in THP-1 cells (Taga-
nov et al., 2006) and miR-223 in T cells (Kumar et al., 2014). We
determined whether DTMs could be induced by pro-inflamma-
tory stimuli in mdx H2K myotubes. TNF-a treatment increased
miR-146a and miR-223 (Figure 6A) whereas pre-treatment with
NFkB-inhibiting anti-inflammatory drugs (prednisolone and
VBP15; Heier et al., 2013) suppressed induction (Figure 6A).
Both drugs also decreased miR-146b and miR-382 levels, with
VBP15 showing greater effects (Figure 6A).
To investigate anti-inflammatory effects in vivo, miRNA levels
were measured in archival samples from prednisolone or
VBP15-treated mdx mice. Mice were 6-month-old mdx or age-
matched wild-type treated for 4 months (Heier et al., 2013).
Both drugs significantly reduced diaphragm miR-146a and
146b levels and slightly reduced miR-223 (Figure 6B).
Archival samples from gastrocnemius of 8-week-old prednis-
olone or VBP15-treated mdx mice were additionally obtained
from a separate study (Heier et al., 2013). Here, both prednisone
and VBP15 reduced miR-146a and miR-223 in comparison to
untreated mice whereas miR-382 was increased in predniso-
lone, but not in VBP15-treated mice (Figure 6C). We also as-
sessed BMDmuscle biopsies (VL; n = 9) with ‘‘mild’’ or ‘‘severe’’
histopathology (Table S4; Figure 6D). In this cohort, five of seven
DTMs were elevated as compared to healthy muscle (Figure S4).
Interestingly, only those DTMs associated with the NFkB
pathway (miR-146a, miR-223, and miR-382) were elevated in
severe versus mild BMD muscle (Figure 6D). Collectively, these
data showNFkB regulates a subset of DTMs and its inhibition re-
duces pathological miRNAs in muscle.
DISCUSSION
Here, we utilize muscle from BMD patients harboring an exon
45–47 to model dystrophin protein variability observed in exon
skipping studies. This enabled us to examine dystrophinports 12, 1678–1690, September 8, 2015 ª2015 The Authors 1681
Figure 2. miRNAs Inhibit Dystrophin Protein Translation In Vitro
(A) Schematic of dystrophin 30 UTR reporter. The human dystrophin 30 UTR was cloned into the 30 end of a Renilla reporter gene (psi-CHECK2 vector). The
psi-CHECK2 vector co-expresses Firefly luciferase and thus provided an internal transfection control.
(B) miRNAs inhibit dystrophin 30 UTR reporter activity. Individually, 14 dystrophin mRNA-targeting miRNAs were co-transfected with reporter into cells; percent
inhibition is provided in graph (n = 4 replicates; ANOVA; **p < 0.01; ***p < 0.001; ****p < 0.0001 versus negative [] control).
(C) Western blot of healthy human myotubes transfected with 50 nM of indicated miRNAs. Tubulin (loading control) and densitometry values (% CTRL) are
provided.
(legend continued on next page)
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Figure 3. DTMs Reduce Dystrophin In Vivo
miRNA pool (called Biomix with 70% or 1.05 mg
miR-146b, 25% or 0.375 mg miR-374a, and 5%
or 0.075 mg miR-31) was injected into TA of
6-week-old C57BL10/J mice (group termed
miRNA; n = 6/group). Equivalent amount of control
was injected into left TA (group termed CTRL).
Muscles were harvested 7 days later.
(A) miRNA injection of wild-type mice to observe
effects on steady-state dystrophin. Left: repre-
sentative immunofluorescence images overlaid
with tattoo dye from bright field to delineate site of
injection; green, tattoo dye; red, dystrophin; white
arrows denote where dystrophin levels are
decreased in miRNA-, but not in CTRL-injected
muscles; scale bars represent 100 mM. Right:
average pixel count (dystrophin levels) around in-
jection site (Student’s t test; *p < 0.05).
(B and C) miRNA injection after injury in wild-type
mice to observe effects of de novo dystrophin
expression. Muscle injury was inflicted using
notexin. Three days post-injection miRNAs were
injected into the right TA; CTRL was injected into
the left. Mice were sacrificed 7 days post-injury
(n = 3/group). (B) miRNAs reduce dystrophin
expression post-injury. Western blot of CTRL or
miRNA-injected muscle to show dystrophin is
shown. Loading controls are provided. (C) Left:
dystrophin immunostaining in CTRL and miRNA-
injected mice is shown. Central nucleation de-
marcates regenerated fibers (blue, DAPI; red,
dystrophin). Right: average pixel count (dystrophin
levels) per field is shown (Student’s t test;
**p < 0.01).
Refer also to Figure S2 and Table S2. In all panels,
error bars represent ± SEM.regulation without confounding variables, such as protein stabil-
ity, attributed to a specific DMD exon deletion (van den Bergen
et al., 2014). Using this method, we provide insight into the
molecular mechanisms contributing to variable dystrophin. We
identify miRNAs that regulate dystrophin and are induced by
inflammation, a feature of dystrophic muscle. Our findings sug-
gest a model for dystrophin variability in muscle and for variable
clinical progression of BMD patients sharing the same exon
deletion (refer to Graphical Abstract). As dystrophic myofibers
remodel, they induce a pro-inflammatory response in distinct
microenvironments, triggering immune cells to release inflam-
matory cytokines, such as TNF-a. This activates NFkB signaling
in myofibers, which induces DTM transcription (miR-146a and
miR-223), which, in turn, inhibits dystrophin translation. These(D) DTMs show synergistic inhibition. The three most potent DTMs (1 nM, miR
combination (referred to as Biomix); results are reported as percent inhibition (n =
control).
(E) Schematic shows base pairing of miRNAs with dystrophin 30 UTR, called miR
four or five nucleotide substitutions were made to reporter (mutated nucleotides
miR-146a (blue). Mutagenesis was performed on one of three miR-374a MREs; h
due to two non-mutated miR-347a MREs remaining (gray).
(F) MREmutagenesis reduces dystrophin inhibition. Fifty-nanomolar indicatedmiR
or a MRE mutant 30 UTR reporter (black bars). Mutated MRE construct matches
t test for wild-type versus mutant; #p < 0.1; *p < 0.05; **p < 0.01).
Refer also to Table S2. In all panels, error bars represent ± SEM.
Cell Reevents could further exacerbate aberrant signaling that occurs
in dystrophic myofibers and initiate a positive feedback loop
that would (1) lead to further increases in DTMs and (2) would
result in decreased, yet variable, dystrophin in individual fibers
andmuscle groups. Chronic activation of these processes would
result in variable clinical phenotypes that would presumably
worsen with age and disease progression. Inhibition of DTMs
could theoretically increase dystrophin in BMD and thus pro-
vides a potential therapeutic target.
Our findings contribute to the knowledge initiated by a few key
bodies of work. One report showed miR-31 is associated with
muscle regeneration and miR-223 is associated with inflamma-
tory infiltration following muscle injury (Greco et al., 2009);
another showed proof of principle that miR-31 can inhibit-146b, miR-374a, and miR-31) were transfected into cells individually or in
4 replicates; ANOVA; **p < 0.01; ***p < 0.001; ****p < 0.0001 versus negative []
NA recognition elements or MREs. MRE mutants were constructed as shown;
in red). For miR-146a/b sequence, x = c, y = a for miR-146b and x = t, y = g for
owever, this mutant was anticipated to have little effect on reporter expression
NAs were co-transfected into cells alongwith dystrophin wild-type (white bars)
transfected miRNA for each condition as indicated (n = 4 replicates; Student’s
ports 12, 1678–1690, September 8, 2015 ª2015 The Authors 1683
Figure 4. DTMs Are Elevated in Dystrophic Muscle and Increase with Age
(A) miRNAs are elevated in dystrophic dogs. Levels of miR-146b, miR-146a, and miR-223 in the vastus lateralis (VL) muscle of 6-month-old GRMD (n = 9)
compared to aged matched wild-type dogs are shown (n = 3; Student’s one tailed t test; #p < 0.1; p < 0.05; **p < 0.01; ***p < 0.001).
(B) DTMs increase with disease progression. Levels of miR-146a, miR-146b, and miR-223 in VL muscle biopsies of 1- and 6-month-old GRMD dogs are shown
(n = 6/group).
(legend continued on next page)
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Figure 5. DTMs Are Inversely Correlated with Exon Skipping Success In Vivo
Four-week-old mdx mice were given PMO (single high intravenous dose; 800 mg/kg) driving exon 23 skipping. Four weeks post-treatment, muscles were
analyzed for miRNA expression via qRT-PCR and for dystrophin via SILAM mass spectrometry (n = 3 muscles).
(A) miRNAs influence intra-variability in dystrophin rescue. Dystrophin and miRNA levels are shown for tibialis anterior (TA), gastrocnemius (gastroc), and dia-
phragm muscle from a single PMO-treated mouse (ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001).
(B) Inter-subject variability in dystrophin rescue influenced by miRNAs. Plot of dystrophin protein as percent wild-type (y axis) and a combinatorial score of seven
miRNAs (miR-146b, miR-374a, miR-31, miR-223, miR-146a, miR-382, andmiR-320a scored as low,moderate, or high; x axis; 63 total measures). Measurements
determined using triceps, TA, and gastroc of treated mdx are shown (ANOVA; **p < 0.01).
In all panels, error bars represent ± SEM.dystrophin in vitro (Cacchiarelli et al., 2011). Furthermore, previ-
ous studies of serum miRNAs show the extent of miRNA dysre-
gulation is linked to age and disease progression (Jeanson-Leh
et al., 2014; Vignier et al., 2013).
DMDmuscle shows variable histopathology that is, in part, due
to asynchronous regeneration (Dadgar et al., 2014), which cre-
ates muscle microenvironments with various degrees of pro-
inflammatory and pro-fibrotic networks. Our proposed model
suggests inflammatory microenvironments influence dystrophin
via DTM induction. Supporting this, previous reports show only
a fraction of healthy donor myoblasts or bone-marrow-derived
cells produce dystrophin in DMD muscle, perhaps due to DTMs
within themusclemicroenvironment (Gussoni et al., 1997;Wernig
et al., 2005). Additionally, here we show an inverse relationship
between DTMs and dystrophin rescue in exon-skipping-treated
mdx.Given this, DTM inhibition may improve exon skipping suc-
cess. Evidence for this includes an in vitro study where co-
transfection of an exon-skipping lentiviral construct (U1 snRNA
antisense) and a locked nucleic acid (LNA) to inhibit miR-31 re-
sulted in increased dystrophin (Cacchiarelli et al., 2011).(C) DTMs increasewith age inmdxmice. Left: DTMs in TA ofmdxmice are shown (
t test; ***p < 0.001; *p% 0.05). Right: representative H&E of cross-sections from T
shown.
(D and E) DTMs are elevated in whole extensor digitorum longus muscle (EDL) a
(D) DTMs in whole EDL of mdx or age-matched wild-type mice are shown (Stude
myofibers from the contralateral EDL of the samemdx andwild-typemice from (D)
(n = 4/group; Student’s t test with Mann-Whitney correction for non-Gaussian dist
all panels, error bars represent ± SEM.
Cell RePreviously, our lab investigated mosaic female DMD carriers
with different proportions of non-mutated dystrophin (Pegoraro
et al., 1995). In these patients, some dystrophin-competent
myonuclei failed to make dystrophin, specifically in older
patients. Here, we show DTMs increase with age in GRMD and
mdx muscle. This suggests age-related increases in miRNAs
may contribute to the previously described failure of dystro-
phin-competent nuclei to produce dystrophin.
miRNA profiling in the aging heart has identified 65 miRNAs
that are differentially expressed (Zhang et al., 2012). This list
included increases in miR-146a, miR-146b, miR-223, and miR-
374a, which we have reported here. A separate study showed
found the aging heart had reduced dystrophin levels (Townsend
et al., 2011), suggesting a link between miRNAs and decreased
cardiac dystrophin during aging.
Most miRNAs described here do not exhibit distinct tissue
specificity. miR-31 is higher in normal human GI and epithelial
tissues (Liang et al., 2007), andmiR-146 is elevated in the murine
heart (Lagos-Quintana et al., 2002). Other reports detect DTMs
in skeletal muscle at different phases of muscle regeneration12 days, n = 3; 8 weeks, n = 4). miR-223 andmiR-31 levels are shown (Student’s
As of 12-day- and 8-week-oldmdxmice where scale bar represents 100 mM is
nd in purified myofibers from mdx EDL.
nt’s t test; n = 4 per group; **p < 0.01; *p < 0.05; #p < 0.1). (E) DTMs in purified
. Note that in (D) and (E), miRNA upregulation ismaintained in purifiedmyofibers
ribution; **p < 0.01; *p < 0.05; #p < 0.1). Refer also to Figure S3 and Table S3. In
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Figure 6. DTMs Are Induced by NFkB-Mediated Inflammation
(A)mdx H-2Kmyotubes treated with indicated drug were induced with TNF-a; DTMs assayed by qRT-PCR. miR-146a and miR-223 increase with TNF-a; VBP15
or prednisolone (Pred) pre-treatment inhibits induction; miR-146b and miR-382 decreased with VBP15, but not Pred (n = 5/group; ANOVA; ****p < 0.0001;
***p < 0.001; **p < 0.01; *p < 0.05; #p < 0.1).
(B) Muscles from 6-month-old mdx mice treated with Pred (5 mg/kg/day) or VBP15 (45 mg/kg/day) as described (Heier et al., 2013). miR-146a, miR-146b, and
miR-223 decreased with both drugs (n = 8/group; ANOVA; ****p < 0.0001; **p < 0.01; *p < 0.05).
(C) Muscles from 8-week-old mdx mice treated with Pred (5 mg/kg/day) or VBP15 (15 mg/kg/day) as described (Heier et al., 2013). miR-146a and miR-223 are
reduced by both drugs, whereas miR-382 increases with Pred, but not VBP15 (n = 5/group; ANOVA; **p < 0.01; *p < 0.05).
(D) DTMs associated with the NFkB pathway are preferentially elevated in severe BMD muscle. Left: representative H&E staining showing mild and severe BMD
pathology is shown. Right: miR-146a, miR-146b, and miR-223 levels in BMD mild and severe muscle (Student’s t test; **p < 0.01; *p < 0.05; #p < 0.1). The scale
bars represent 200 mM.
Refer also to Table S4 and Figure S4. In all panels, error bars represent ± SEM.(Greco et al., 2009). We found elevated DTMs in purified mdx
myofibers, suggesting muscle-specific miRNA expression. We
also show TNF-a induces miR-146a and miR-223 in mdx myo-
tubes, whereas NFkB inhibition attenuates induction. Although
DTMs described here are not classically defined as myomiRs,
previous reports show non-muscle-specific miRNAs are also
imperative for proper muscle function (Nova´k et al., 2013). One1686 Cell Reports 12, 1678–1690, September 8, 2015 ª2015 The Aureport shows miR-146b, miR-31, and miR-223, known as
dystromiRs, are differentially expressed in dystrophic muscle
and have been shown to play a role in myogenesis and muscle
regeneration (Roberts et al., 2012). Other reports show miR-
146b-5p promotes myogenic differentiation (Khanna et al.,
2014; Kuang et al., 2009) and miR-31 and miR-223 are induced
in ischemia-damaged myofibers (Greco et al., 2009). Supportingthors
this, here we show DTM induction during myoblast differentia-
tion. Together, these data suggest DTMs play a role in normal
muscle regeneration.
Inflammatory cells could contribute to DTM induction in
dystrophic muscle. In this scenario, ‘‘crosstalk’’ between im-
mune cells andmyofibers could bemediated by horizontal trans-
fer of miRNAs by exosomes or microvesicles (Ismail et al., 2013;
Kosaka et al., 2010; Mittelbrunn et al., 2011; Skog et al., 2008;
Valadi et al., 2007; Zhang et al., 2010). Although there are knowl-
edge gaps in the mechanism of RNA transfer from immune to
other cells, it is plausible that miRNAs could behave similar to
endocrine peptide hormones, where distant cytokines induce a
positive autocrine/paracrine feedback loop (Clevenger and
Plank, 1997).
We show TNF-a-mediated NFkB activation induces DTM
expression in dystrophic myotubes. This supports previous
studies that identified NFkB consensus elements in miR-146a/
miR-223 promoters (Kumar et al., 2014; Taganov et al., 2006).
In treating DMD, patients undergoing exon-skipping therapy
will likely be co-administered glucocorticoids. One inclusion
criteria for recent exon-skipping trials was >24 weeks of gluco-
corticoid treatment (Mendell et al., 2013). Glucocorticoids glob-
ally effect inflammation and gene transcription, which could
impact DTM expression. Here, we show prednisolone and
VBP15 reduce DTMs miR-146a, miR-146b, and miR-223, sug-
gesting these drugs could increase dystrophin if combined
with exon skipping. Prednisolone also increased miR-382,
whereas VBP15 had no effect. This difference could be ex-
plained by the ability of VBP15 to dissociate glucocorticoid-
receptor-mediated transactivation activity. These data suggest
anti-inflammatory compounds such as prednisolone and partic-
ularly VBP15 could enhance exon skipping success (Heier et al.,
2013).
It is conceivable that DTMs are involved in other muscle
disorders where NFkB signaling is enhanced. Interestingly, a
previous report showed elevated DTMs in a wide variety of
muscle disorders such as myositis, Miyoshi myopathy, and
limb girdle muscular dystrophy (Eisenberg et al., 2007).
Thus, DTMs may be a common signature of muscle diseases
where chronic inflammation is present and could potentially
provide therapeutic targets for a broader range of muscle
disorders.
Consistent with our findings, a previous study showed that
miR-31 represses dystrophin through the 30 UTR (Cacchiarelli
et al., 2011), results that were validated here. In dystrophic mus-
cles, we detected miR-31 at lower absolute levels than other
DTMs. miR-31 did not increase in GRMD muscle and was not
associated with exon skipping success in mdx mice. Thus,
whereas miR-31 was one of seven DTMs characterized, others
appeared more relevant to both disease progression and
therapeutics.
Our work here elicits questions regarding the role of the dys-
trophin 30 UTR in normal muscle, given the abundance of
miRNA binding sites and the high conservation of this region.
One model revolves around remodeling of myofibers in healthy
muscle. Myofibers are one of the more morphologically adapt-
able cells, and activity can result in rapid cell hypertrophy or
atrophy. The normal function of dystrophin is to provide a rigidCell Remembrane cytoskeleton and robust connections between intra-
cellular contracting myofibrils and the extracellular matrix. How-
ever, myofibers need to transiently destabilize the membrane
cytoskeleton to remodel (Kee et al., 2004). Given previous re-
ports showing that lengthening muscle contractions result in
reduced dystrophin (Komulainen et al., 1998), it is possible that
the ‘‘normal’’ role of DTMs is to enable transient dystrophin
reduction in remodeling myofibers.
Here, we show proof of principle that dystrophin is reduced by
inflammation-induced miRNAs that are elevated in dystrophic
muscle. Our data provide insight into phenotypic discrepancies
observed in BMD and variable success observed in DMD
exon-skipping clinical trials. We show NFkB inhibition, in addi-
tion to quelling inflammation, may provide the added benefit of
increasing de novo dystrophin production. This work could
potentially provide an avenue for molecular-based therapy for
BMD patients and an adjuvant therapy in DMD to increase
exon skipping effectiveness.
EXPERIMENTAL PROCEDURES
Muscle Biopsies
All details are provided in the Supplemental Experimental Procedures.
Western Blot Analysis
Muscle protein was extracted from cryosections with lysis buffer containing
75mM Tris-HCl (pH 6.8), 10%SDS, 10mMEDTA, and 5% 2-mercaptoethanol
as described (Yokota et al., 2009). Additional detail is in the Supplemental
Experimental Procedures.
TaqMan miRNA Low-Density Arrays
RNA was extracted from 20 mg muscle (ten BMD; five DMD; six control) with
TRIzol (Life Technologies). miRNA array was performed with TaqMan low-
density Array A (TaqMan Array Human miRNA, v3.0A; 382 miRNAs; Applied
Biosystems; Life Technologies). Single-stranded cDNA was synthesized
from 100 ng RNA using TaqMan MiRNA Reverse Transcription Kit (Life
Technologies) and RNA-specific stem-looped Megaplex RT Primers, Human
Pool A v2.1 (Life Technologies). Additional details are in the Supplemental
Experimental Procedures.
qRT-PCR Assays
mRNA
Total RNA was extracted from muscle biopsies (20 mg) using TRIzol (Life
Technologies) according to manufacturer’s instructions with isopropanol pre-
cipitation performed at 20C overnight. Total RNA was reverse-transcribed
to cDNA using Qscript cDNA synthesis kit (Quanta) and then analyzed using
human-specific TaqMan probes (Life Technologies) and the 7900HT Fast
Real-Time PCR system. For TaqMan gene expression assay IDs, refer to Table
S3. Muscle-specific gene expression was normalized to titin (TTN). Results
were calculated using the 2DDCq method (Livak and Schmittgen, 2001).
Mouse gene expression was quantified in the same manner as above, with
mouse-specific TaqMan probes (Life Technologies; refer to Table S3).
miRNA
Human miRNAs were quantified using Taqman miRNA low-density array
(TLDA) assays as above from RNA extracted from 20 mg of muscle. Mouse
and dog miRNAs were quantified (20 mg muscle) using TaqMan assays (Life
Technologies) according to manufacturer’s protocol. Table S4 lists all miRNA
assay IDs.
Luciferase Assays
C2C12 myoblasts (30 UTR assay) or HEK293 cells (mutagenesis assay) were
seeded in 24-well plates at a density of 4 3 104 or 8 3 104 cells/well and
co-transfected 24 hr later with 200 ng dystrophin 30 UTR or mutant reporterports 12, 1678–1690, September 8, 2015 ª2015 The Authors 1687
and with 50 nM miRNA mimics (Life Technologies) with Lipofectamine 2000.
Cells were harvested 24 hr later according to Dual-Glow Luciferase Reporter
Assay System protocol (Promega). Results were normalized to an internal con-
trol driven by a separate promoter in the same reporter. Results are reported as
percent change by setting negative control values to 0%. Biomix details are in
the Supplemental Experimental Procedures.
miRNA Transfections in Immortalized Human Myoblasts
Immortalized human myoblasts were seeded on 0.4% gelatin in 6-well plates
(2.5 3 105 cells/well) with skeletal muscle proliferation media. Cells were co-
transfected with 50 nM of indicated miRNA mimics using Lipofectamine
2000. Cells were differentiated with 2% horse serum for 5 days and then lysed
as described (Yokota et al., 2009). miRNA delivery was verified via Cy3-labeled
CTRL (Life Technologies; AM17120).
Immunofluorescence
Seven-micrometer sections were cut frommouse TAs. Sections were air dried,
hydrated in PBS, and stained for dystrophin as reported (Lu et al., 2000).
Image J software (NIH) was used for analysis; average pixel intensity was
measured after images were set to a 70-pixel threshold and converted to a
binary image. Full details are in the Supplemental Experimental Procedures.
TNF-a Treatment of mdx H2K Myotubes
H2Kmyoblasts were differentiated into myotubes in 12-well plates (1.253 105
cells/well) with Matrigel at 37C. After 4 days of differentiation, myotubes were
treated with 1 mMVBP15 or prednisolone for 6 hr and then induced with TNF-a
(10 ng/ml) for 24 hr.
Dystrophin Quantification with Mass Spectrometry
Dystrophin protein was quantified using 50 mg of total protein mixed with 25 mg
of SILAM internal standard as reported (Brown et al., 2012). Full details are in
the Supplemental Experimental Procedures.
Animal Studies
All animal studies were done in adherence to the NIH Guide for the Care and
Use of Laboratory Animals, and experiments were conducted within IACUC
guidelines under approved protocols. All studies were reviewed and approved
by the Institutional Animal Care and Use Committee of Children’s National
Medical Center. Mice were obtained from The Jackson Laboratory.
Single Myofiber Isolation
Single myofibers were prepared from the EDL muscle of 8-week-old mdx
(C57BL/10ScSn-Dmd<mdx>/J) and wild-type (C57BL/10ScSnJ) mice as
described (Rosenblatt et al., 1995).
Intramuscular miRNA Mimic Injections
Six C57BL/10ScSnJ (wild-type) mice aged 6 weeks were injected with 1.5 mg
miRNA Biomix (Life Technologies) or control (Cy3-labeled CTRL miRNA; Life
Technologies; AM17120) with tattoo dye to demarcate injection site. Injection
was followed by electroporation (2 3 80 V pulses over 20 ms with 980 ms in
between pulses) to increase delivery. TAs were harvested after 7 days, snap
frozen in liquid-nitrogen-cooled isopentane, and stored at 80C.
Notexin-Induced Muscle Damage followed by miRNA Mimic
Injections
Muscle injury was induced by injecting 6-week-old C57BL/10ScSnJ (wild-
type) mice with 10 ml of 10 mg/ml notexin (n = 3). The TAwas surgically exposed
(incisions <1cm in length), and tattoo dye marked injection location. Skin was
closed with sutures to minimize pain and tissue damage for second injection.
Three days later, 10 mg of miRNAs was injected into the right TA; a scrambled
Cy3-labeled control mimic (CTRL) was injected into the left TA. The muscles
were harvested 7 days post-injury.
Systemic Delivery of PMOs
Four-week-old mdx mice (C57BL/10ScSn-Dmd<mdx>/J) were given a
single 800 mg/kg dose of PMO (Gene Tools): 50-GGCCAAACCTCGGCT
TACCTGAAAT-30, administered through retro-orbital injection (n = 3). Four
weeks post-injection (at 8 weeks of age), mice were euthanized via carbon
dioxide inhalation; muscles were harvested as described above. Dystrophin
protein and miRNA levels were compared to age-matched wild-type controls.1688 Cell Reports 12, 1678–1690, September 8, 2015 ª2015 The AuVBP15 and Prednisone Administration
Archival samples from two separate studies were obtained. The first set was
from a prophylactic trial where 2-week-old mdx mice (C57BL/10ScSn-
Dmd<mdx>/J) were dosed with 5 mg/kg prednisolone or 15 mg/kg VBP15
as reported (Heier et al., 2013). The second set was from an ‘‘adult trial’’ where
6-week-oldmicewere dosedwith 5mg/kg prednisolone (5mg/kg) or 45mg/kg
VBP15 for 4months (Heier et al., 2013). Total RNAwas extracted from gastroc-
nemius (mice sacrificed at 8weeks) or diaphragm (mice sacrificed at 6months),
and miRNA levels were assessed.
Statistical Analysis
For assays with greater than two groups, measurements were compared
between groups using one-way ANOVA unless otherwise indicated. Post
hoc linear tests between each group were performed; the resulting p value
reported in figures was adjusted for multiple testing by Sidak method
unless otherwise indicated. The contrasting groups in all post hoc compari-
sons are indicated in each figure. For assays with two groups where the null
hypothesis was testing a change in one direction, a one-tailed, Student’s
t test was utilized, whereas in assays where the potential change between
groups was + or, a two-tailed Student’s t test was utilized. For all bar graphs,
data are presented as ± SEM. Details of both tests are specified in the figure
legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.07.066.
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